Indaptus Therapeutics, Inc. current report, 23 July 2021

Full document

Indaptus Therapeutics, Inc. — Form 8-K Summary

Reporting context: The filing was submitted by Intec Parent, Inc., the successor entity associated with Intec Israel, with a report date of July 23, 2021 and signature date of July 29, 2021. It reports a private placement, the domestication merger, a reverse share split, and related securities transactions. The filing does not provide operating-period financial results.

Key Transaction and Financial Details

  • The company entered into a securities purchase agreement for a private placement of a pre-funded warrant for up to 2,727,273 common shares and a warrant for up to 2,727,273 common shares.
  • The purchase price was $10.99 per pre-funded warrant and associated warrant. Gross proceeds were expected to be approximately $29.9 million, or approximately $30 million assuming full exercise of the pre-funded warrant, before placement fees and offering expenses.
  • The pre-funded warrant has a $0.01-per-share exercise price and is exercisable upon issuance. Beneficial ownership limitations generally restrict exercise above 4.99%, adjustable up to 9.99% with 61 days’ notice.
  • The warrant has a five-and-one-half-year term, is immediately exercisable, and has an $11.00-per-share exercise price, subject to customary adjustments.
  • Placement-agent compensation includes a 7.0% cash fee, a 1.75% management fee, $25,000 of non-accountable expenses, $50,000 of legal expenses, and warrants for up to 136,364 shares with a $13.75-per-share exercise price.
  • The filing provides no revenue, profit, cash flow, margin, debt, liquidity balance, or other conventional operating metrics.

Material Changes and Corporate Transactions

  • The private placement was intended to satisfy a closing condition for the Decoy Biosystems merger and was expected to close immediately before the merger, targeted for approximately August 3, 2021, subject to customary conditions.
  • On July 27, 2021, the domestication merger was completed. Domestication Merger Sub merged with Intec Israel, with Intec Israel surviving as a wholly owned subsidiary of Intec Parent.
  • Intec Israel ordinary shares converted on a one-for-one basis into Intec Parent common stock, while outstanding Intec Israel options and warrants were exchanged for equivalent securities of the company.
  • A 1-for-4 reverse share split became effective after the close of trading on July 26, 2021, before the domestication merger.
  • Following the transactions, the common stock began trading on Nasdaq under the symbol NTEC. The post-transaction CUSIP was 45828B 100.
  • The Israel Tax Authority issued a ruling addressing the tax treatment of the share exchange for qualifying “Interested Public” shareholders, subject to specified conditions.

Registration, Outlook, and Risks

  • The company agreed to file a resale registration statement for the shares underlying the pre-funded warrant and warrant within 30 days of signing and to seek effectiveness within 45 days if not reviewed by the SEC, or within 75 days if reviewed.
  • Liquidated damages may apply if the company fails to meet the filing, effectiveness, or maintenance obligations under the registration rights agreement.
  • The private placement was an unregistered offering under Section 4(a)(2) and Rule 506 of Regulation D. The securities were not registered under the Securities Act and may be resold only under an effective registration statement or an applicable exemption.
  • Closing remained subject to customary conditions, representations, warranties, covenants, indemnification obligations, and termination provisions.
  • The tax ruling is conditional and applies only to shareholders meeting specified requirements, including ownership, acquisition, and status limitations.
  • The filing contains no formal financial guidance or operating outlook.

Investor Verification Items

  • Confirm whether the private placement and Decoy merger ultimately closed, and determine the actual net proceeds after fees and expenses.
  • Verify the number of common shares outstanding after the reverse split, domestication merger, and warrant issuances.
  • Review the final warrant agreements for adjustment provisions, exercise limitations, and potential dilution.
  • Confirm the filing and effectiveness dates of the resale registration statement and whether any liquidated damages were incurred.
  • Review subsequent periodic filings for cash balances, liquidity runway, debt, operating expenses, merger accounting, and the financial impact of the transactions.